Navigation Links
Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic
Date:2/10/2009

ex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's therapeutic approach is markedly different from gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco, CA and in Ottawa, Canada in 2006, with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Light-speed nanotech: Controlling the nature of graphene
2. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
3. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
7. Genetic clock makers at UC San Diego publish their timepiece in Nature
8. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
9. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. New yeast trick for eating favorite food: Details in Nature paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 ... cancer death in American men. One in ... and 233,000 new cases are diagnosed annually. That ... are using a powerful new technique, MRI Fusion ... and large cancer lesions, treating only the affected ...
(Date:9/1/2015)... , Sept. 1, 2015 The Dohmen ... Floyd , Ph.D., MBA as Chief Science Officer ... this newly created role, Dr. Floyd will lead ... a portfolio of pre-commercial and post approval outsourced ... and medical communications.  Dr. Floyd brings decades of ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
(Date:8/31/2015)... 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... orders are for air emission abatement projects in ... a large order for a municipality in the ... a competitor,s system that failed to meet the customer,s requirements. This ... said Derek S. Webb , President and Chief Executive ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
... DIEGO, Sept. 2 NuVasive, Inc. (Nasdaq:,NUVA), a ... disruptive surgical treatments for the spine, announced today,that ... Kevin,O,Boyle, Executive Vice President and Chief Financial Officer, ... Healthcare Unplugged,Conference at the Grand Hyatt New York ...
... Sept. 2 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced the ... Michael J. LaBarre, PhD, Vice President, Product ... "Halozyme is committed to attracting, developing, ...
... Mallinckrodt acknowledges validity of Purdue patents; Purdue licenses ... limited sales of some generic oxycodone strengths, STAMFORD, ... and Mallinckrodt Inc. of Hazelwood, Missouri have,agreed to end ... them in the United States District,Court for the Southern ...
Cached Biology Technology:NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015 ... on consumers that are active and healthy. However, ... in the hospital environment to help improve diagnostic ... a video from the Wearable Technologies Conference ... discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... laboratory research has shown that resveratrol, a common dietary supplement, ... of breast cancer, suggesting a potential role for the agent ... in red wine and red grapes. It is sold in ... stores. "Resveratrol has the ability to prevent the ...
... non-Hodgkin,s lymphoma in the developing world might benefit from ... ESMO Conference Lugano (ECLU) organized by the European Society ... Azim from Cairo University reports that giving these patients ... as usual, improved treatment outcomes. The standard regimen ...
... marine creatures as clams, sand dollars and lobsters showed ... with no clear trend afterwards, according to an international ... increases beginning 248 million years ago and may shed ... in the past are analogies for what is happening ...
Cached Biology News:Researchers identify cancer preventive properties in common vitamin supplement 2New treatment approach promising for lymphoma patients in the developing world 2Ancient marine invertebrate diversity less explosive than thought 2Ancient marine invertebrate diversity less explosive than thought 3
... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
... This reagent has been developed for ... the reduction of nonspecific background staining ... methods describe blocking peroxidase with hydrogen ... peroxide in combination with additional novel ...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Biology Products: